Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 70 | ECE2020 | Next issue

22nd European Congress of Endocrinology

05 Sep 2020 - 09 Sep 2020

Card image cap
Europe's leading endocrinology congress showcasing the very best in the study and treatment of endocrine disorders.

Oral Communications

Pituitary and Neuroendocrinology

ea0070oc4.1 | Pituitary and Neuroendocrinology | ECE2020

Quantitative mRNA expression of PROK2, DUSP6, and WDR11 in peripheral blood as diagnostic criteria for central hypogonadism

Loktionova Anna , Ilovayskaya Irena , Nefedova Lidia

Central hypogonadism (CH) is a syndrome that can be diagnosed in women with hypoestrogenic amenorrhea and a lack of normal response of gonadotropins to hypoestrogenemia in the absence of other reasons. To date, about 50 genes were reported as a possible reason for this condition, but the genetic basis is still unknown for approximately a half of CH cases.Patients and Methods: Some of the CH-related genes are expressing in leukocytes of peripheral blood: ...

ea0070oc4.2 | Pituitary and Neuroendocrinology | ECE2020

Both ghrelin deletion and unacylated ghrelin overexpression preserve muscles in aging mice

Agosti Emanuela , De Feudis Marilisa , Angelino Elia , Belli Roberta , Alves Teixeira Maraiza , Zaggia Ivan , Raiteri Tommaso , Scircoli Andrea , Graziani Andrea , Prodam Flavia , Sanpaolesi Maurilio , Costelli Paola , Ferraro Elisabetta , Reano Simone , Filigheddu Nicoletta

Sarcopenia, the decline in muscle mass and functionality during aging, might arise from age-associated endocrine dysfunction. Indeed, muscle wasting follows the general decline in trophic hormones and the establishment of a chronic mild inflammatory status characteristic of aging. Ghrelin is a gastric hormone peptide circulating in both acylated (AG) and unacylated (UnAG) forms that have anti-atrophic activity on skeletal muscle. AG is the endogenous ligand of the growth hormo...

ea0070oc4.3 | Pituitary and Neuroendocrinology | ECE2020

Clinical implications of Pan-genomic classification of pituitary neuroendocrine tumours

Villa Chiara , Neou Mario , Armignacco Roberta , Anne Jouinot Anne , Raffin-Sanson Marie-Laure , Septier Amandine , Perlemoine Karine , Bernier Michèle , Baussart Bertrand , Bertherat Jerome , Gaillard Stéphan , Assié Guillaume

Recently, we provided the first integrated genomic classification of pituitary neuroendocrine tumors (PitNETs), on a series of 134 tumors. This series covered all histological, secretion, invasion and growth speed types. This molecular classification supports the importance of pituitary lineage as proposed by the World Health Organization 2017 classification, but also individualizes new entities. Indeed, corticotroph tumors are split into three distinct molecular groups. In ad...

ea0070oc4.4 | Pituitary and Neuroendocrinology | ECE2020

Thyrotropin/Thyrotropin receptor signaling deficiency impairs spatial learning and memory

Luan Sisi , Hou Xu , He Zhao , Zhao Jiajun

Purpose: Subclinical hyperthyroidism is associated with cognitive impairment, but the mechanism has remained unclear. As subclinical hyperthyroidism is characterized by significantly decreased thyrotropin (TSH) levels, this study aimed to investigate whether TSH regulates cognitive function.Methods: The correlation between TSH and cognitive impairment was investigated in a cross-sectional population study including 382 participants wi...

ea0070oc4.5 | Pituitary and Neuroendocrinology | ECE2020

Durability of response and gender-based analysis from the LINC3 trial of osilodrostat in the treatment in cushing’s disease

Pivonello Rosario , Fleseriu Maria , Newell-Price John , Xavier Bertagna , James Findling , Akira Shimatsu , Feng Gu , Richard Auchus , Rattana Leelawattana , Jig Lee Eun , Hee Kim Jung , Andre Lacroix , Biller Beverly

Introduction: In a Phase II study, osilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD. We report the efficacy and safety of osilodrostat in a large CD patient population (NCT02180217).Methods: In this study, open-label osilodrostat was initiated at 2 mg bid in 137 adults with CD and mUFC > 1.5 × ULN, with dose adjustments every 2 weeks (range 1–30 mg bid) up to ...

ea0070oc4.6 | Pituitary and Neuroendocrinology | ECE2020

Results from the phase 3, randomized, double-blind, placebo-controlled OPTIMAL study of oral octreotide capsules in adult patients with acromegaly

Samson Susan , Nachtigall Lisa , Fleseriu Maria , Gordon Murray , Ludlam William , Patou Gary , Haviv Asi , Molitch Mark E , Biermasz Nienke , Strasburger Christian J , Kennedy Laurence , Melmed Shlomo

Background: Many patients with acromegaly report limitations of long-acting somatostatin receptor ligand (SRL) injections, including ongoing disease symptoms near cycle-end and injection-site pain. Oral octreotide capsules (OOC) may provide an alternative to monthly injections. The phase 3 CHIASMA OPTIMAL study assessed efficacy and safety of OOC in patients with acromegaly controlled on injectable SRLs.Methods: A multinational, randomized, placebo-contr...

ea0070oc4.7 | Pituitary and Neuroendocrinology | ECE2020

Fluid restriction results in a modest rise in plasma sodium concentration in chronic hyponatraemia due to SIAD; results of a prospective randomised controlled trial

Garrahy Aoife , Galloway Iona , Hannon Anne Marie , Dineen Rosemary , O’Kelly Patrick , Tormey William , O’Reilly Michael , Williams David , Sherlock Mark , Thompson Chris

Fluid restriction (FR) is the recommended first-line treatment for chronic hyponatraemia due to syndrome of inappropriate antidiuresis (SIAD) in expert guidelines, despite the lack of prospective data to support its efficacy. We aimed to test the hypothesis that FR was more effective than no treatment. 46 patients with chronic SIAD were randomised to either fluid restriction (1 litre/day, FR) or no specific hyponatraemia treatment (NoTx) for one month. Inclusion criteria were ...